About Aptose Biosciences
Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: APTO
- Previous Close: $1.13
- 50 Day Moving Average: $1.13
- 200 Day Moving Average: $1.55
- 52-Week Range: $0.83 - $4.30
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.97
- P/E Growth: 0.00
- Market Cap: $15.20M
- Outstanding Shares: 13,455,000
- Beta: 1.29
- Return on Equity: -139.94%
- Return on Assets: -121.78%
Companies Related to Aptose Biosciences:
- Current Ratio: 5.29%
- Quick Ratio: 5.29%
Earnings History for Aptose Biosciences (NASDAQ:APTO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Aptose Biosciences (NASDAQ:APTO)
Current Year EPS Consensus Estimate: $-1.15 EPS
Next Year EPS Consensus Estimate: $-1.17 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Aptose Biosciences (NASDAQ:APTO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Aptose Biosciences (NASDAQ:APTO)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Aptose Biosciences (NASDAQ:APTO)
What is Aptose Biosciences' stock symbol?
Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."
Where is Aptose Biosciences' stock going? Where will Aptose Biosciences' stock price be in 2017?
5 analysts have issued twelve-month price targets for Aptose Biosciences' shares. Their predictions range from $7.00 to $12.00. On average, they expect Aptose Biosciences' share price to reach $9.75 in the next year.
What are analysts saying about Aptose Biosciences stock?
Here are some recent quotes from research analysts about Aptose Biosciences stock:
According to Zacks Investment Research, "Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. " (11/17/2016)
Oppenheimer Holdings, Inc. analysts commented, "Aptose announced June 8 an agreement with CrystalGenomics for an exclusive global option and license for CrystalGenomics’ CG026806. CG026806 is a non- covalent small molecule inhibitor of Bruton’s tyrosine kinase (BTK), FMS-like tyrosine kinase 3 (FLT3) and the Aurora kinases (AURK). Aptose will make its decision on its option mid-2017 after executing IND-enabling studies. We reiterate our Outperform rating and $17 price target." (6/9/2016)
Who owns Aptose Biosciences stock?
Aptose Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (9.83%).
Who sold Aptose Biosciences stock? Who is selling Aptose Biosciences stock?
Aptose Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc..
How do I buy Aptose Biosciences stock?
Shares of Aptose Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Aptose Biosciences stock cost?
One share of Aptose Biosciences stock can currently be purchased for approximately $1.13.
Aptose Biosciences (NASDAQ:APTO) Chart for Friday, February, 24, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart